GlassScriptPhysician profile
Elliot L Levine
NPI 1356305775
$4,178.45
in general payments reported to CMS, 2019-2025
19 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $289 · 2021: $1,472 · 2022: $191 · 2023: $220 · 2024: $1,386 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $1,045 · Food and Beverage: $931 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $1,045.00 |
| Food and Beverage | $930.94 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $1,072.57 | 2021 | |
| Ocular Therapeutix, INC. | $1,045.00 | 2024 | Dextenza |
| Alcon Vision LLC | $527.45 | 2020-2025 | Rocklatan, Tryptyr, Centurion |
| Bausch & Lomb Americas INC. | $234.19 | 2022-2024 | Miebo, Vyzulta, Xiidra |
| Allergan, INC. | $231.24 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $172.93 | 2019-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $151.52 | 2020-2025 | Tecnis Simplicity, Veritas Vision System |
| Sun Pharmaceutical Industries INC. | $144.56 | 2020-2025 | |
| Carl Zeiss Meditec USA, INC. | $128.02 | 2021-2023 | Quatera 700 |
| Harrow Eye, LLC | $108.31 | 2024-2025 | Iheezo, Vevye |
| Tarsus Pharmaceuticals, INC. | $101.23 | 2024 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $65.43 | 2019-2020 | |
| Oyster Point Pharma, INC. | $40.09 | 2022 | |
| Abbvie INC. | $38.42 | 2024-2025 | |
| Dompe US, INC. | $34.07 | 2025 | Oxervate |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32.03 | 2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $18.48 | 2021 | |
| Abb Con-Cise Optical Group LLC | $17.07 | 2019 | |
| Medline Industries LP | $15.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.